Charles River Laboratories: Underperforming the Healthcare Sector?

Charles River Laboratories International (CRL) stock has underperformed the healthcare sector, with a 31% decline from its 52-week high and a 22.1% drop over the past three months. Despite better-than-expected Q4 results and a consensus rating of "Moderate Buy," analysts remain cautious about CRL's prospects. The stock's recent underperformance and bearish trend, trading below its 200-day moving average, suggests a bearish outlook.